Amylyx Pharmaceuticals Inc. (AMLX)
$32.49
$0.40
(1.25%)
As on 11-Sep-2026 11:35EDT
Market cap
$3,800 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
15.8
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
37.91
-
EV/EBITDA
-11.7
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-1.5
-
Face value
--
-
Shares outstanding
111,423,048
5 Years Aggregate
CFO
$-290.14 Mln
EBITDA
$-295.70 Mln
Net Profit
$-296.64 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Amylyx Pharmaceuticals (AMLX)
| 169.0 | 43.3 | 141.4 | 174.6 | 16.6 | -- | -- |
|
BSE Sensex
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Amylyx Pharmaceuticals (AMLX)
| 219.6 | -74.0 | -60.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Amylyx Pharmaceuticals (AMLX)
|
32.5 | 3,799.5 | 0.0 | -152.1 | -- | -55.9 | -- | 15.8 |
| 16.8 | 6,074.3 | 3,117.6 | 157.4 | 14.7 | -- | 36.3 | 188.5 | |
| 224.4 | 10,826.1 | 776.6 | -191.6 | -17.6 | -223.4 | -- | 131.0 | |
| 72.5 | 14,630.7 | 691.8 | -696.2 | -89.1 | -- | -- | 123.7 | |
| 112.9 | 12,065.9 | 830.8 | 54.9 | 3.2 | 8.1 | 248 | 17.3 | |
| 11.9 | 10,020.9 | 332,834.2 | 33,166.6 | 11.1 | 8.9 | 29.3 | 2.5 | |
| 22.9 | 12,236.5 | 5,020.0 | -199.0 | 1.6 | -3 | -- | 1.9 | |
| 285.2 | 5,693.6 | 290.5 | 197.2 | 82.5 | 19.9 | 29.8 | 5.9 | |
| 68.6 | 6,145.7 | 450.9 | 138.6 | 39.1 | 115.6 | 49 | 30.7 | |
| 126.9 | 8,210.6 | 431.8 | -136.7 | -30.8 | -30.3 | -- | 19.0 |
Shareholding Pattern
View DetailsAbout Amylyx Pharmaceuticals (AMLX)
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an... investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. Read more
-
Co-Founder, Co-CEO & Director
Mr. Joshua B. Cohen
-
Co-Founder, Co-CEO & Director
Mr. Joshua B. Cohen
-
Headquarters
Cambridge, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Amylyx Pharmaceuticals (AMLX)
What is the current share price of Amylyx Pharmaceuticals Inc (AMLX) Today?
The share price of Amylyx Pharmaceuticals Inc (AMLX) is $32.49 (NASDAQ) as of 11-Sep-2026 11:35 EDT. Amylyx Pharmaceuticals Inc (AMLX) has given a return of 16.55% in the last 3 years.
What is the current PB & PE ratio of Amylyx Pharmaceuticals Inc (AMLX)?
Since, TTM earnings of Amylyx Pharmaceuticals Inc (AMLX) is negative, P/E ratio is not available.
The P/B ratio of Amylyx Pharmaceuticals Inc (AMLX) is 15.76 times as on 04-Sep-2026, a 105 premium to its peers’ median range of 7.69 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-7.89 |
3.74 |
2024 |
-0.86 |
1.57 |
2023 |
20.67 |
2.35 |
2022 |
-12.18 |
7.10 |
2021 |
-- |
-- |
What is the 52 Week High and Low of Amylyx Pharmaceuticals Inc (AMLX)?
The 52-week high and low of Amylyx Pharmaceuticals Inc (AMLX) are Rs 41.14 and Rs 10.83 as of 11-Sep-2026.
What is the market cap of Amylyx Pharmaceuticals Inc (AMLX)?
Amylyx Pharmaceuticals Inc (AMLX) has a market capitalisation of $ 3,800 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Amylyx Pharmaceuticals Inc (AMLX)?
Before investing in Amylyx Pharmaceuticals Inc (AMLX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.